IDH1 and central nervous system cancer: Following the identification of potential RNaseH2 inhibitors via high-throughput screening, we selected the most potent inhibitors for further analysis, both as single agents and in combination with TMZ (30 μM) in the glioma cell line U87MG (U87WT in the following) and U87MG cells with monoallelic expression of the IDH1 R132H mutant (U87MUT in the following).